Cytokinetics Inc (CYTK): Price Down $-0.35 (-1.11)% Over Past Day, Down $-0.13 (-0.42)% Over Past Hour

The Hourly View for CYTK

At the time of this writing, CYTK (Get Ratings)’s price is down $-0.13 (-0.42%) from the hour prior. CYTK has seen its price go down 5 out of the past 5 hours, thus creating some compelling opportunities for bears. As for the trend on the hourly timeframe, we see the clearest trend on the 100 hour timeframe. The moving averages on the hourly timeframe suggest a choppiness in price, as the 20, 50, 100 and 200 are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.

Out of Pharmaceutical Products stocks, CYTK ranks 185th in regards to today’s price percentage change.

CYTK’s Technical Outlook on the Daily Chart

At the moment, CYTK’s price is down $-0.35 (-1.11%) from the day prior. The daily chart shows that CYTK has seen 3 straight down days. If you’re a trend trader, consider that the strongest clear trend on the daily chart exists on the 100 day timeframe. The moving averages on the daily timeframe suggest a bullishness in price, as the 20, 50, 100 and 200 are all in a bullish alignment — meaning the shorter durations are above the longer duration averages, implying a sound upward trend. The chart below shows CYTK’s price action over the past 90 days.

CYTK: Daily RSI Analysis

• For CYTK, its RSI is now at 0.
• CYTK and RSI may be exhibiting divergent trends. This may be something to monitor.

For CYTK News Traders

Investors and traders in CYTK may be particularly interested in the following story that came out in the past day:

Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host a conference call and webcast on September 13, 2021 at 8:30 AM Eastern Time to discuss the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM). Members of Cytokinetics’ management will be joined by Marty Maron, M.D., Director, Hypertrophic Cardiomyopathy Center; Director, Cardiac CT and MRI; Tufts Univ

Want More Great Investing Ideas?

9 “MUST OWN” Growth Stocks for 2021

5 WINNING Stock Chart Patterns

7 Best ETFs for the NEXT Bull Market